Q&A: How a new imaging tool helps to better stage prostate cancer
Q&A by Doctor Jeremie Calais on how PSMA PET imaging [...]
Scandium radionuclides for theranostic applications
Learn more about the upcoming new radionuclide family of Scandium: [...]
Patient Management with Lu-177–PSMA-617 in the Clinic
Patient Management and Operationalizing Lutetium-177–PSMA-617 for Metastatic Castration Resistant Prostate [...]
Health Policy Partnership Framework
The Oncidium foundation is endorsing the Health Policy Partnership Framework, [...]
PSMA Theranostics: Current Landscape and Future Outlook
Cancers 2021, 13(16), 4023; https://doi.org/10.3390/cancers13164023, August 10, 2021, by Hanbo [...]
Lu-177-PSMA-617A Added to Standard Therapy
VISION Trail Results Indicate Benefit of 177Lu-PSMA-617A Added to Standard [...]
Theranostic Approach in Breast Cancer
Theranostic Approach in Breast Cancer: A Treasured Tailor for Future [...]
FDA for Lu-177-PSMA-617 for mCRPC treatment
Targeted Oncology, Sarah Karlovitch, June 17, 2021 The FDA has [...]
Global Nuclear Medicine Market 2013-2025
Key slide by MEDraysintell used at the SNMMI virtual meeting [...]
Drugmakers push into radio pharmaceuticals
Dolgin, E. Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nat Biotechnol 39, 647–649 [...]